Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2020Proceedings of the National Academy of SciencesOpen Access

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSuzanne J. F. KapteinRega Institute for Medical ResearchSJSofie JacobsJanssen (Belgium)LLLana LangendriesRega Institute for Medical Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kaptein et al. (2020) studied this question.

synapsesocial.com/papers/69ff7fb46018b8d0892d867chttps://doi.org/10.1073/pnas.2014441117
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐192020 · 100 citations
  2. 2Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data2015 · 2,413 citations
  3. 3Clinical characteristics of 82 cases of death from COVID-192020 · 593 citations
  4. 4Mutagenesis in Norovirus in Response to Favipiravir Treatment2018 · 49 citations
  5. 5Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial2020 · 796 citations